摘要
弥漫大B细胞淋巴瘤（DLBCL）是成年人最常见的淋巴肿瘤，占所有非霍奇金淋巴瘤的30％-40％。利妥昔单抗联合化疗是DLBCL的标准治疗方案。尽管三分之二以上患者一线治疗后可缓解，但仍有近三分之一的患者难以经诱导缓解，常表现为难治或早期复发，特别是高危（高国际预后指数评分）或伴MYC基因异常者，可使该类患者获得长期缓解的治疗方案不多。第57届美国血液学会（ASH）年会对于复发、难治、高危、双表达淋巴瘤及特殊类型DLBCL治疗方面的进展进行了详细报道，文章就此进行总结。
Diffuse large B-cell lymphoma （DLBCL） is one of the most common non-Hodgkin lymphoma accounting for 30 %-40 %. The most common first-line therapy for DLBCL is rituximab in combination With chemotherapy. About two thirds of patients treated by the first-line therapy achieve a complete remission （CR） and are cured finally, but nearly one third of patients can not reach CR after frontline treatment appearing refractory or relapse early, especially for the high risk patients or cases with MYC alterations, the regimen improving the long-term survival is not much. In the 57th American Society of Hematology （ASH） annual meeting, a plenty of treatment as focus on these patients brought in encouraging results, which makes it possible to further improve the CR rate. The progresses on DLBCL of relapse and refractory, high risk and special types were summarized in this paper based on the reports in the 57th ASH annual meeting.
出处
《白血病．淋巴瘤》
CAS
2016年第1期19-22,共4页
Journal of Leukemia & Lymphoma
关键词
淋巴瘤
大B-细胞
弥漫性
治疗
美国血液学会年会
Lymphoma, large B-cell, diffuse
Therapy
American Society of Hematology annual meeting
